Skip to content

Alpelisib

Piqray (alpelisib) is a small molecule pharmaceutical. Alpelisib was first approved as Piqray on 2019-05-24. It is used to treat breast neoplasms and male breast neoplasms in the USA. It has been approved in Europe to treat breast neoplasms. The pharmaceutical is active against phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform. In addition, it is known to target phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform, phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform, and phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform. Piqray's patents are valid until 2030-09-28 (FDA).
Trade Name Piqray
Common Name Alpelisib
Indication breast neoplasms, male breast neoplasms
Drug Class Phosphatidylinositol 3-kinase inhibitors
Alpelisib
Get full access now